Abstract
Presentation Description :
Human induced pluripotent stem cells (hiPSC) provide a unique tool for the development of in vitro models of retinal diseases as well as therapeutic strategies to regenerate the diseased retina. Recent progress in our ability to generate hiPSC-derived three dimensional retinal tissue that closely mimic the in vivo retinal microenvironment and tissue organization open new frontiers for their use in clinical applications. This talk will present and overview of the current-state-of-the art in hiPSC-derived retinal organoids; discuss the challenges and opportunities these systems present for clinical applications; and outline the current efforts at CellSight, the Ocular Stem Cell and Regeneration Research Program at the University of Colorado, to translate hiPSC-retinal organoid technology into cell-based therapies to treat retinal degenerative diseases.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.